Orient EuroPharma Co., Ltd. (4120.TWO)

Orient EuroPharma Co., Ltd. (4120.TWO) — VMCI valuation read

Composite valuation read on 4120.TWO: VMCI 44/100 against a Healthcare sector median of 50. The 6-point below-median print is the headline number for Orient EuroPharma Co., Ltd., and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.

Trailing 30-day insider activity for 4120.TWO: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.

**Investor frame.** Value, quality, risk in three lines on 4120.TWO: 4120.TWO trades at 19.0x earnings, 6% above the Healthcare median of 18.0x; ROIC of 9.0% trails the Healthcare median (10.0%) by 1.0pp; net debt to EBITDA of 3.0x is the rate-sensitivity line to watch. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.

4120.TWO fell 0.6% over the trailing 7 days, with a -3.2% read on a 30-day basis.